VLP Vaccine Technology

VLP疫苗技术

• 批准号: 8785650
• 负责人: SANG-MOO KANG
• 金额: $ 72.63万
• 依托单位: GEORGIA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-01-15 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8785650
• 关键词: Adjuvant; Animal Model; Antibodies; Antigen Targeting; Antigen-Presenting Cells; Centers for Disease Control and Prevention (U.S.); Cessation of life; Collaborations; Cotton Rats; Data; Development; Disease; Feasibility Studies; Ferrets; Figs - dietary; Flagellin; Formalin; Future; Goals; Health; Hepatitis B Virus; Human; IACUC; Immunity; Infant; Influenza; Injection of therapeutic agent; Intramuscular; Licensing; Life; Ligands; Lung diseases; MF59; Membrane; Methods; Modeling; Molecular; Morphology; Mus; Needles; Oral; Palivizumab; Papillomavirus; Pharmaceutical Preparations; Production; Protocols documentation; Public Health; Rattus; Recombinants; Research Personnel; Respiratory Syncytial Virus Vaccines; Respiratory syncytial virus; Safety; Skin; Staging; Structure; System; TLR4 gene; Tandem Repeat Sequences; Technology; Testing; Therapeutic; Time; Vaccination; Vaccine Adjuvant; Vaccines; Viral; Virulence; Virus; Virus-like particle; aluminum sulfate; base; biodefense; efficacy evaluation; efficacy testing; egg; immunogenicity; improved; influenza virus vaccine; influenzavirus; mortality; mouse model; new technology; novel; novel vaccines; oral vaccine; pathogen; preclinical efficacy; prevent; product development; protective efficacy; recombinant virus; respiratory; vaccine candidate; vaccine delivery; vaccine development; vaccine efficacy

DESCRIPTION (provided by applicant): Virus-like particles (VLPs) provide great potential to develop future vaccines against highly pathogenic viral pathogens. VLPs mimic the virus in structure and morphology, but are non-infectious, featuring a high safety profile. The goal of our proposed project is to develop vaccine technology based on recombinant VLPs. Respiratory syncytial virus (RSV) and influenza virus are important respiratory viral pathogens. There is no licensed vaccine against RSV. There are 9 times more deaths by RSV than those by influenza among young infants. The fact that licensed RSV drugs are based on antibodies highly supports the possibility to develop an effective RSV vaccine. We have developed RSV VLP vaccines that are proven to be effective in preventing RSV enhanced disease from recent feasibility studies. However, RSV VLP vaccine technology is in an early stage of development and much study is needed to provide sufficient preclinical efficacy data of RSV VLP vaccines. We hypothesize that RSV VLP vaccines developed in our feasibility studies will be highly effective in inducing protective immunity against RSV. In the specific aim 1, we will focus on obtaining sufficient proof-of-concept efficacy data of RSV VLP vaccines as well as testing long-term immunity and non-needle delivery technologies (intranasal, microneedle skin, and oral vaccination). As for aim 2, we will develop antigen targeting vaccine adjuvant systems by using molecularly adjuvanted VLP technology and test licensed adjuvants. Also, utilizing VLP vaccine technology, we have developed a promising universal influenza VLP vaccine and obtained sufficient proof-of-concept efficacy data, which is expected to significantly improve the current egg-substrate based influenza vaccines. In the aim 3, we will extend the preclinical efficacy tests of VLP vaccines to cotton rats (RSV VLPs) and ferrets (novel universal influenza VLPs). VLP vaccines proposed in this application will provide an excellent system to prove VLP vaccine technologies which are also applicable to other biodefense pathogens.

描述（由申请人提供）：病毒样颗粒（VLP）提供了针对高度致病病毒病原体开发未来疫苗的巨大潜力。 VLP模仿结构和形态的病毒，但没有感染，具有高安全性。我们拟议的项目的目的是开发基于重组VLP的疫苗技术。呼吸综合病毒（RSV）和流感病毒是重要的呼吸病毒病原体。没有针对RSV的许可疫苗。 RSV死亡的死亡人数是年轻婴儿中流感的9倍。许可的RSV药物基于抗体的事实高度支持开发有效的RSV疫苗的可能性。我们开发了RSV VLP疫苗，这些疫苗被证明可有效防止最近可行性研究中的RSV增强疾病。但是，RSV VLP疫苗技术正处于开发的早期阶段，需要大量研究来提供RSV VLP疫苗的足够临床前疗效数据。我们假设在我们的可行性研究中开发的RSV VLP疫苗将在诱导防止RSV的保护性免疫方面非常有效。在特定目标1中，我们将专注于获得RSV VLP疫苗的足够概念验证疗效数据，以及测试长期免疫力和非针对性递送技术（鼻内，微对照皮肤和口服疫苗）。至于AIM 2，我们将使用分子辅助VLP技术和测试许可佐剂开发靶向疫苗辅助系统的抗原。同样，利用VLP疫苗技术，我们开发了一种有希望的通用流感VLP疫苗，并获得了足够的概念验证疗效数据，预计该数据将显着改善当前基于卵的流感疫苗。在AIM 3中，我们将将VLP疫苗的临床前疗效测试扩展到棉大鼠（RSV VLP）和雪貂（新型通用流感VLP）。本应用程序中提出的VLP疫苗将为证明VLP疫苗技术提供出色的系统，该系统也适用于其他生物诱变病原体。